Vanillic acid
Based on 3 publication(s) in Google Scholar
Vanillic acid is a flavoring agent found in edible plants and fruits, also found in Angelica sinensis. Vanillic acid inhibits NF-κB activation. Anti-inflammatory, antibacterial, and chemopreventive effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.43%
- CAS. Nr.: 121-34-6
- Formel: C8H8O4
- Molecular Weight:168.15
-
Speicherung:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Vanillic acid
MoreAlle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
p65 |
Microbial Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against human A549 cells after 24 hrs by MTT assay
Anticancer activity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| A549 | IC50 |
>30 μM
Compound: 20
|
Anticancer activity against human A549 cells by SRB assay
Anticancer activity against human A549 cells by SRB assay
|
[PMID: 21420296] |
| A549 | IC50 |
>100 μM
Compound: 16
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| A549 | IC50 |
>100 μg/mL
Compound: 5
|
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26995526] |
| B16-F10 | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against mouse B16F10 cells after 24 hrs by MTT assay
Anticancer activity against mouse B16F10 cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| B16-F10 | IC50 |
9.24 mM
Compound: Vanillic acid
|
Cytotoxicity against mouse B16-F10 cells assessed inhibition of cell growth incubated for 24 hrs by MTT assay
Cytotoxicity against mouse B16-F10 cells assessed inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 36095944] |
| Hs 683 | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against human Hs683 cells after 24 hrs by MTT assay
Anticancer activity against human Hs683 cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| HT-22 | EC50 |
27.8 μM
Compound: 36
|
Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay
Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay
|
[PMID: 32991171] |
| HT-29 | IC50 |
>100 μg/mL
Compound: 5
|
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26995526] |
| HUVEC | IC50 |
>100 μg/mL
Compound: 5
|
Antiproliferative activity against human HUVEC cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human HUVEC cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26995526] |
| LoVo | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against human LoVo cells after 24 hrs by MTT assay
Anticancer activity against human LoVo cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| LoVo | IC50 |
91 μM
Compound: 16
|
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| MCF7 | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against human MCF7 cells after 24 hrs by MTT assay
Anticancer activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| MCF7 | IC50 |
>100 μg/mL
Compound: 5
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26995526] |
| OE33 | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against human OE33 cells after 24 hrs by MTT assay
Anticancer activity against human OE33 cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| PC-3 | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against human PC3 cells after 24 hrs by MTT assay
Anticancer activity against human PC3 cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| PC-3 | IC50 |
>100 μM
Compound: 16
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| RAW264.7 | IC50 |
23.2 μM
Compound: 9
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay
|
[PMID: 25666824] |
| SK-MEL-2 | IC50 |
>30 μM
Compound: 20
|
Anticancer activity against human SK-MEL-2 cells by SRB assay
Anticancer activity against human SK-MEL-2 cells by SRB assay
|
[PMID: 21420296] |
| SK-MEL-28 | IC50 |
>100 μM
Compound: 16
|
Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay
Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| SK-OV-3 | IC50 |
>30 μM
Compound: 20
|
Anticancer activity against human SKOV3 cells by SRB assay
Anticancer activity against human SKOV3 cells by SRB assay
|
[PMID: 21420296] |
| T98G | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against human T98G cells after 24 hrs by MTT assay
Anticancer activity against human T98G cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| U-373MG ATCC | IC50 |
>1000 μM
Compound: 1b
|
Anticancer activity against human U373 cells after 24 hrs by MTT assay
Anticancer activity against human U373 cells after 24 hrs by MTT assay
|
[PMID: 20466556] |
| U-373MG ATCC | IC50 |
>100 μM
Compound: 16
|
Cytotoxicity against human U373 cells after 72 hrs by MTT assay
Cytotoxicity against human U373 cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| XF498 | IC50 |
>30 μM
Compound: 20
|
Anticancer activity against human XF498 cells by SRB assay
Anticancer activity against human XF498 cells by SRB assay
|
[PMID: 21420296] |
Vanillic acid is non-toxic to HT22 cells at all three concentrations (50, 100 and 200?μM); Vanillic acid co-treatment with Aβ1-42 significantly increases (1.5-, 1.9- and 2-fold respectively) cell viability[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT22 cells
-
Concentration:50, 100 and 200 μM
-
Incubation Time:24 hours
-
Result:Increased the viability of HT22 cells after 24 h at three different concentrations (50, 100 and 200 μM).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Swiss mice (25-30 g)[1]
-
Dosage:3, 10, or 30 mg/kg
-
Administration:Intraperitoneal treatment; 5 hours
-
Result:Inhibited Carrageenan-induced mechanical hyperalgesia, paw edema, and neutrophil and macrophage recruitment.
Chemical Information
-
CAS. Nr. 121-34-6
-
Appearance Solid
-
Molecular Weight 168.15
-
Formel C8H8O4
-
Color Off-white to light brown
-
SMILES
O=C(O)C1=CC=C(O)C(OC)=C1
-
Structure Classification
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Antioxidants (Basel)
Bioactive Extracts and Constituents from Taraxacum mongolicum: Antioxidant, Anti-Inflammatory, Enzyme-Inhibitory, and Molecular Docking Studies. [Abstract]2026 May 29;15(6):688. PMID: 42351994 -
Food Funct
Blackthorn juice from central Italy exhibits selective anticancer activity by inducing apoptosis and autophagy in gastric carcinoma cells. [Abstract]2025 Oct 27;16(21):8548-8563. PMID: 41085359 -
Mol Nutr Food Res
Therapeutic Potential of Vanillic Acid in Ulcerative Colitis Through Microbiota and Macrophage Modulation. [Abstract]2025 Jan 15:e202400785. PMID: 39812000
Lösungsmittel & Löslichkeit
DMSO : ≥ 100 mg/mL (594.71 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Calixto-Campos C, et al. Vanillic acid Inhibits Inflammatory Pain by Inhibiting Neutrophil Recruitment, Oxidative Stress, Cytokine Production, and NFκB Activation in Mice. J Nat Prod. 2015 Aug 28;78(8):1799-808. [Content Brief]
[2]. Amin FU, et al. Vanillic acid attenuates Aβ1-42-induced oxidative stress and cognitive impairment in mice. Sci Rep. 2017 Jan 18;7:40753. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.9471 mL | 29.7357 mL | 59.4714 mL | 148.6785 mL |
| 5 mM | 1.1894 mL | 5.9471 mL | 11.8943 mL | 29.7357 mL | |
| 10 mM | 0.5947 mL | 2.9736 mL | 5.9471 mL | 14.8679 mL | |
| 15 mM | 0.3965 mL | 1.9824 mL | 3.9648 mL | 9.9119 mL | |
| 20 mM | 0.2974 mL | 1.4868 mL | 2.9736 mL | 7.4339 mL | |
| 25 mM | 0.2379 mL | 1.1894 mL | 2.3789 mL | 5.9471 mL | |
| 30 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL | 4.9560 mL | |
| 40 mM | 0.1487 mL | 0.7434 mL | 1.4868 mL | 3.7170 mL | |
| 50 mM | 0.1189 mL | 0.5947 mL | 1.1894 mL | 2.9736 mL | |
| 60 mM | 0.0991 mL | 0.4956 mL | 0.9912 mL | 2.4780 mL | |
| 80 mM | 0.0743 mL | 0.3717 mL | 0.7434 mL | 1.8585 mL | |
| 100 mM | 0.0595 mL | 0.2974 mL | 0.5947 mL | 1.4868 mL |